Early Impact of 13-valent Pneumococcal Conjugate Vaccine Use on Invasive Pneumococcal Disease among Adults with and without Underlying Medical Conditions-United States.
The 13-valent pneumococcal vaccine (PCV13) was introduced for U.S. children in 2010, and for immunocompromised adults ≥19 years old in series with the 23-valent polysaccharide vaccine (PPSV23) in 2012. To quantify indirect effects before the 2014 introduction of PCV13 for all adults ≥65 years old, we evaluated PCV13 impact on invasive pneumococcal disease (IPD) among adults with and without PCV13 indications. We estimated IPD incidence using Active Bacterial Core surveillance and National Health Interview Survey. We compared incidence in 2013-2014 and 2007-2008, by age and serotype group (PCV13, PPSV23-unique, or types in neither vaccine [NVT]), among adults with and without PCV13 indications. IPD incidence declined among all adults. Among adults 19-64 years, PCV13-type IPD declined 57% (95%CI:-68,-43) in adults with immunocompromising conditions (IC, indication for PCV13 use), 57% (95%CI:-62, -52) in immunocompetent adults with chronic medical conditions (CMC, indications for PPSV23 use alone), and 74% (95%CI:-78,-70) in adults with neither vaccine indication. Among adults ≥65 years, PCV13-type IPD decreased 68% (95%CI:-76,-60) in those with IC, 68% (95%CI:-72,-63) in those with CMC, and 71% (95%CI:-77,-64) in healthy adults. PPSV23-unique types increased in adults 19‒64 years with CMC, and NVT did not change among adults with or without PCV13 indications. From 2013-2014, non-PCV13 serotypes accounted for nearly 80% of IPD. IPD incidence among U.S. adults declined after PCV13 introduction in children. Similar reductions in PCV13-type IPD in those with and without PCV13 indications suggest observed benefits are largely due to indirect effects from pediatric PCV13 use rather than direct use among adults.